secwatch.observer — SEC 8-K summary
======================================

Issuer:     Calidi Biotherapeutics, Inc. (CLDI)
CIK:        0001855485
Form:       8-K
Filed at:   2024-11-15T23:59:59+00:00
Accession:  0001493152-24-046330
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 1.01, 3.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Calidi Biotherapeutics closes $7.5M public offering of 4.44M shares at $1.69/share
--------------------------------------------------------------------------------

- Gross proceeds ~$7.5M from 4,437,869 shares at $1.69; closed Nov 15, 2024.
- Net proceeds for working capital, general corporate purposes, and pre-clinical/clinical trials.
- Placement agent Ladenburg Thalmann gets 8% cash fee, 1% mgmt fee, and warrants for 221,893 shares at $2.1125.
- Lock-ups: company 15 days, insiders 90 days; CEO may sell up to 10K shares after 25 days for tax planning.
- Offering under effective S-3 shelf; proceeds expected to extend cash runway for clinical-stage biotech.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1855485/000149315224046330/0001493152-24-046330-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1855485/000149315224046330/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-046330

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer